Last updated: September 7, 2026
Gemtuzumab ozogamicin, marketed as Mylotarg by Pfizer, is a CD33-directed antibody-drug conjugate approved for adults with newly diagnosed or relapsed or refractory acute myeloid leukemia (AML), and for pediatric patients aged 1 month and older with newly diagnosed CD33-positive AML. Its commercial trajectory has been defined by an initial launch, withdrawal after safety and confirmatory-efficacy problems, and a narrower 2017 reapproval under revised dosing and patient-selection criteria.[1]
Mylotarg is strategically important as a targeted AML therapy but is no longer a major Pfizer revenue driver. Pfizer does not separately disclose Mylotarg revenue in its public financial reporting. The product competes in a fragmented AML market against intensive chemotherapy, venetoclax-based regimens, CPX-351, FLT3 inhibitors, IDH inhibitors, antibody-drug conjugates, clinical trials, and allogeneic stem-cell transplantation.
What is gemtuzumab ozogamicin and how does it work?
Gemtuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized anti-CD33 monoclonal antibody linked to the cytotoxic agent calicheamicin. CD33 is expressed on most AML blasts and on myeloid precursor cells. After binding to CD33, the conjugate is internalized and releases calicheamicin, which causes DNA damage and cell death.[1]
| Product attribute |
Detail |
| Brand |
Mylotarg |
| Active ingredient |
Gemtuzumab ozogamicin |
| Product type |
Antibody-drug conjugate |
| Target |
CD33 |
| Payload |
Calicheamicin derivative |
| Sponsor |
Pfizer |
| Primary disease |
Acute myeloid leukemia |
| FDA approval |
Initial approval in 2000; reapproval in 2017 |
| Administration |
Intravenous infusion |
| Regulatory classification |
Biologic drug approved through an NDA framework |
| Primary commercial issue |
Narrow addressable population and substantial safety-management requirements |
The product is not a broad AML treatment. Its value depends on CD33 expression, disease setting, patient fitness, induction strategy, cytogenetic or molecular profile, and the availability of alternative regimens.
When did Mylotarg lose exclusivity and commercial momentum?
Mylotarg’s commercial decline began before conventional market exclusivity ended. The decisive event was Pfizer’s voluntary withdrawal from the U.S. market in 2010 after the required postmarketing study failed to confirm clinical benefit and identified excess mortality and veno-occlusive disease concerns.[2]
The FDA approved a reformulated and re-dosed version in 2017 after clinical data supported lower fractionated dosing and more selective use. The product therefore experienced two separate commercial phases:
| Period |
Market status |
Commercial implication |
| 2000-2010 |
U.S. approval and commercial launch |
Initial targeted-therapy adoption in AML |
| 2010-2017 |
U.S. withdrawal |
Loss of commercial continuity and prescriber momentum |
| 2017 onward |
Reapproved under revised dosing and indications |
Smaller, safety-focused relaunch |
| Current market phase |
Mature niche oncology product |
Limited standalone revenue visibility and strong therapeutic competition |
A conventional patent-expiration date does not fully explain Mylotarg’s financial trajectory. The product’s effective loss of commercial momentum resulted from clinical and safety events, market withdrawal, and the emergence of competing AML therapies.
What is the FDA regulatory status of gemtuzumab ozogamicin?
Mylotarg is FDA-approved for several AML settings, including:
- Newly diagnosed CD33-positive AML in adults.
- Newly diagnosed CD33-positive AML in pediatric patients aged 1 month and older.
- Relapsed or refractory CD33-positive AML in adults and pediatric patients aged 2 years and older.
The 2017 approval incorporated a fractionated dosing schedule for some adult regimens and removed the prior broad treatment framework. The FDA labeling contains boxed warnings and prominent precautions relating to hepatotoxicity, including hepatic veno-occlusive disease, infusion-related reactions, hemorrhage, and embryo-fetal toxicity.[1]
The product’s regulatory value is therefore tied to careful patient selection and administration. Hospitals must manage liver function, infusion reactions, cytopenias, infection risk, and transplant-related considerations.
What clinical evidence supports Mylotarg?
The regulatory basis for reapproval included studies such as ALFA-0701, which evaluated gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed AML. The study reported improved event-free survival, but the safety profile required modified dosing and careful patient management.[3]
The product has stronger commercial logic in patients with:
- CD33-positive disease.
- Newly diagnosed AML receiving intensive therapy.
- Relapsed or refractory disease where alternatives are limited.
- Treatment plans in which a targeted agent can improve remission or measurable residual disease outcomes.
The evidence is less commercially compelling when clinicians favor venetoclax-based lower-intensity therapy, CPX-351, mutation-directed treatment, or clinical-trial enrollment.
How large is the gemtuzumab ozogamicin market?
The addressable market is limited by the size of the AML population, CD33 expression, patient fitness, treatment line, and physician willingness to use an intensive or toxicity-sensitive regimen.
AML incidence in the United States is materially smaller than the incidence of common solid tumors. The patient population is also heterogeneous. Older adults, who represent a large share of AML cases, may be unable to receive intensive chemotherapy combinations commonly associated with gemtuzumab use.[4]
Market demand is divided across:
| Market segment |
Mylotarg relevance |
| Fit, newly diagnosed adults |
Moderate, particularly with CD33-positive AML and intensive induction |
| Pediatric newly diagnosed AML |
Relevant, but treatment is concentrated in specialized centers |
| Relapsed or refractory AML |
Relevant where targeted salvage therapy is appropriate |
| Older or frail adults |
More limited because venetoclax-based regimens are widely used |
| CD33-negative disease |
No meaningful target-based rationale |
| Post-remission or transplant settings |
Selective use based on clinical strategy |
Mylotarg is therefore a specialty-hospital product rather than a mass-market oncology drug. Treatment concentration in academic centers and AML referral hospitals can support clinical use but limits broad commercial expansion.
What is the financial trajectory of Mylotarg?
Pfizer does not report Mylotarg as a separate revenue line in its public annual reports. Its sales are incorporated into broader reporting categories, preventing a reliable standalone revenue series from public filings.[5]
The financial trajectory can be characterized qualitatively:
- Initial launch created a targeted AML revenue opportunity.
- Safety concerns and failure of the confirmatory study led to withdrawal and loss of commercial value.
- The 2017 reapproval restored market access but under narrower clinical conditions.
- Post-relaunch revenue has remained commercially modest relative to Pfizer’s major oncology products.
- Competitive pressure and the lack of a broad label limit the probability of material growth.
Mylotarg’s economic value is more likely to arise from portfolio retention, hospital access, and treatment differentiation than from large-scale revenue generation.
What factors limit Mylotarg revenue?
The main revenue constraints are:
- Small eligible patient population.
- CD33-expression requirement.
- Intravenous administration and hospital-based use.
- Hepatic veno-occlusive disease risk.
- Need for specialist monitoring.
- Competition from venetoclax combinations and mutation-directed agents.
- Physician preference for clinical trials or lower-intensity treatment in older adults.
- Prior market withdrawal, which weakened commercial continuity.
- Lack of publicly disclosed standalone sales data.
The 2017 relaunch also required rebuilding physician confidence. A product that has exited the market can face slower re-adoption even after regulatory reapproval.
Which companies and drugs compete with gemtuzumab ozogamicin?
Mylotarg competes with treatment regimens rather than one direct substitute.
| Competitor or regimen |
Company or sponsor |
Competitive relevance |
| Venetoclax plus azacitidine or decitabine |
AbbVie and partners |
Major option for older or unfit AML patients |
| CPX-351, marketed as Vyxeos |
Jazz Pharmaceuticals |
Intensive therapy option for therapy-related AML and AML with myelodysplasia-related changes |
| Midostaurin |
Novartis |
FLT3-mutated AML |
| Gilteritinib |
Astellas |
Relapsed or refractory FLT3-mutated AML |
| Ivosidenib |
Servier |
IDH1-mutated AML |
| Enasidenib |
Servier |
IDH2-mutated AML |
| Azacitidine and decitabine |
Multiple manufacturers |
Lower-intensity backbone therapies |
| Allogeneic stem-cell transplantation |
Academic and transplant centers |
Curative-intent consolidation for selected patients |
| Clinical-trial agents |
Multiple biotechnology companies |
Competes for eligible patients and treatment slots |
Mylotarg’s strongest differentiation is its CD33-targeted mechanism. Its weakness is that it does not address the molecularly defined subgroups targeted by FLT3 or IDH inhibitors and requires a treatment setting in which its safety profile is acceptable.
What patents protect gemtuzumab ozogamicin?
Mylotarg was developed from intellectual property covering the anti-CD33 antibody, antibody-drug conjugate architecture, calicheamicin linkage, and use in AML. The early patent estate is now mature relative to the product’s 2000 launch.
The most commercially important patent categories were:
| Patent category |
Protected subject matter |
Current commercial significance |
| Anti-CD33 antibody |
Humanized antibody and antigen binding |
Likely mature relative to initial launch |
| ADC composition |
Antibody linked to calicheamicin derivative |
Core product composition |
| Conjugation chemistry |
Linker and drug-antibody attachment |
Manufacturing and product identity |
| Therapeutic use |
Treatment of CD33-positive AML |
Narrower protection than composition claims |
| Manufacturing process |
Conjugation, purification, and quality control |
Potential technical barrier, subject to claim scope |
Public Pfizer filings do not provide a standalone current patent-by-patent Mylotarg revenue or exclusivity analysis. The product’s commercial protection is also affected by biologic complexity, manufacturing know-how, regulatory requirements, and the absence of a simple generic substitution pathway.
What formulation patents protect Mylotarg?
The principal technical protection relates to the ADC composition, linker-payload chemistry, antibody production, and manufacturing controls rather than a conventional small-molecule tablet formulation. Mylotarg is an injectable lyophilized product that requires reconstitution and intravenous administration.[1]
Potential follow-on barriers include:
- Consistent antibody-drug ratio.
- Payload loading and conjugation control.
- Aggregation and impurity control.
- Stability during storage and reconstitution.
- Comparability of a follow-on biologic or ADC.
- Bioassay and potency characterization.
These barriers can delay competition even when foundational composition claims have expired. They do not guarantee long-term exclusivity.
Are there Paragraph IV challenges or biosimilar risks?
Mylotarg is a biologic drug, so a conventional Hatch-Waxman generic challenge is less central than a biosimilar or follow-on biologic pathway. A Paragraph IV certification may be relevant to patents listed for an NDA product, but the principal competitive route for a biologic is an abbreviated biologics license application under the Public Health Service Act.
As of the latest broadly available public regulatory information through 2024:
- No widely commercialized Mylotarg biosimilar has established market share in the United States.
- No biosimilar has displaced Mylotarg in the manner seen with mature monoclonal antibodies such as trastuzumab or rituximab.
- The economic incentive for a biosimilar is limited by the small AML market and complex ADC manufacturing.
- Competitive risk is more immediate from alternative AML regimens than from a direct Mylotarg biosimilar.
A follow-on ADC would face analytical, manufacturing, clinical, and commercial hurdles. The product’s limited market size reduces the attractiveness of a costly biosimilar development program.
What is the Orange Book and Purple Book status of Mylotarg?
Mylotarg was approved as a biologic drug using an NDA framework, while the FDA’s biologics reference-product system is generally associated with the Purple Book. FDA product records and labeling confirm the reference product and its indications, but publicly available sources do not establish a commercially active patent dispute comparable to those surrounding major small-molecule oncology products.[1,6]
The key practical issue is not only listed-patent status. A challenger would also need to address:
- Reference-product designation.
- Biosimilarity or interchangeability requirements.
- ADC analytical comparability.
- Manufacturing validation.
- Clinical pharmacology.
- Hospital purchasing and formulary adoption.
- Small commercial opportunity.
What patent litigation affects gemtuzumab ozogamicin?
No major active U.S. patent litigation has materially shaped Mylotarg’s current market position in the public record through 2024. The product’s principal commercial disruption was regulatory and clinical rather than litigation-driven.
The 2010 withdrawal followed concerns about safety and failure to confirm benefit, not a patent settlement. The 2017 return to market followed new clinical evidence and revised dosing, not the resolution of a major generic-entry lawsuit.[2,3]
What generic launch scenarios exist for Mylotarg?
Three scenarios are commercially plausible:
| Scenario |
Timing logic |
Market effect |
| No direct follow-on entrant |
Small market and complex ADC manufacturing discourage development |
Pfizer retains niche hospital demand |
| Limited biosimilar or follow-on ADC entry |
Developer accepts specialized manufacturing and regulatory costs |
Price pressure in selected hospital accounts |
| Therapeutic displacement |
Venetoclax combinations, CPX-351, mutation-directed drugs, or trials gain share |
Mylotarg declines without direct generic competition |
The third scenario is the most important. Mylotarg can lose market share even if no biosimilar launches because AML treatment is increasingly segmented by age, fitness, molecular profile, and treatment objective.
How strong is the Mylotarg patent estate?
Mylotarg has a technically complex product profile but a mature commercial patent position. Its strongest barriers are likely to be manufacturing complexity, specialized clinical use, and regulatory know-how. Its weaker barriers are product age, limited market size, and the absence of broad market exclusivity comparable to a recently launched oncology biologic.
Patent strength should therefore be assessed in four dimensions:
| Dimension |
Assessment |
| Foundational composition patents |
Mature |
| Formulation and manufacturing know-how |
More relevant than basic composition protection |
| Method-of-use protection |
Narrow and dependent on patient setting |
| Commercial durability |
Moderate to weak because therapeutic substitution is substantial |
How does Mylotarg compare with other AML therapies?
Mylotarg is differentiated by CD33 targeting and its use in selected newly diagnosed or relapsed AML patients. Venetoclax-based treatment has broader relevance in older or unfit patients. CPX-351 is positioned around specific high-risk AML categories. FLT3 and IDH inhibitors provide biomarker-directed options that Mylotarg cannot replace.
Mylotarg is most competitive where:
- CD33 is present.
- Intensive treatment is appropriate.
- The treating center has experience managing ADC-related toxicity.
- A targeted addition to chemotherapy is clinically preferred.
- The patient’s molecular profile does not create a stronger alternative.
It is less competitive where low-intensity therapy, targeted molecular treatment, or transplantation dominates the treatment plan.
Key Takeaways
- Gemtuzumab ozogamicin is a CD33-targeted antibody-drug conjugate marketed as Mylotarg.
- Pfizer withdrew the product in 2010 and regained U.S. approval in 2017 under narrower indications and revised dosing.
- Mylotarg has a specialty AML market and does not represent a major separately reported Pfizer revenue stream.
- Pfizer does not disclose standalone Mylotarg sales, so a precise revenue trajectory cannot be calculated from public filings.
- The most important competitive risks come from venetoclax combinations, CPX-351, FLT3 inhibitors, IDH inhibitors, transplantation, and clinical trials.
- Direct biosimilar risk is currently limited by market size, ADC manufacturing complexity, and regulatory requirements.
- The product’s patent position is mature; manufacturing and regulatory barriers are more commercially relevant than basic composition exclusivity.
- Mylotarg’s future value depends on continued use in selected CD33-positive AML patients rather than broad market expansion.
FAQs About Gemtuzumab Ozogamicin Market Dynamics
Is Mylotarg still commercially available?
Yes. Mylotarg was withdrawn from the U.S. market in 2010 and reapproved by the FDA in 2017 for selected CD33-positive AML indications.[1,2]
Does Pfizer disclose Mylotarg revenue?
No. Pfizer does not report Mylotarg as a separate revenue line in its public financial statements.[5]
Is gemtuzumab ozogamicin a biosimilar target?
Potentially, but it is a difficult biosimilar target because it is an antibody-drug conjugate with complex conjugation chemistry, analytical requirements, and manufacturing controls.
What is the main clinical substitute for Mylotarg?
There is no single substitute across all AML patients. Venetoclax-based regimens are important competitors in older or unfit patients, while CPX-351, FLT3 inhibitors, IDH inhibitors, transplantation, and clinical trials compete in defined segments.
Why did Mylotarg lose commercial momentum?
The principal causes were safety concerns, failure of the required confirmatory study, U.S. withdrawal in 2010, and subsequent competition from newer AML treatments.[2,3]
References
- U.S. Food and Drug Administration. (2022). Mylotarg (gemtuzumab ozogamicin) prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2010). FDA approves voluntary withdrawal of Mylotarg. https://www.fda.gov
- Castaigne, S., Pautas, C., Terre, C., Raffoux, E., Recher, C., de Botton, S., ... Fenaux, P. (2012). Effect of gemtuzumab ozogamicin on survival of adult patients with acute myeloid leukemia. Journal of Clinical Oncology, 30(4), 392-398.
- National Cancer Institute. (2024). Acute myeloid leukemia statistics. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov
- Pfizer Inc. (2024). Annual report and Form 10-K. https://www.pfizer.com/investors/financial-reports
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
